Budesonide orodispersible tablet (Jorveza®) is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||04/12/2018|
|Rapid review completed||28/01/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of budesonide orodispersible tablet compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
|Full pharmacoeconomic assessment commissioned by the HSE||30/01/2019|
|Pre-submission consultation with Applicant||26/05/2020|
|Current status||Awaiting HTA submission from Applicant|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.